Skip to Content

Geovax Labs Inc GOVX Stock Quote

| Rating as of

NASDAQ:GOVX

Morningstar‘s Stock Analysis GOVX

Valuation
Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Key Statistics GOVX

Company Profile GOVX

Business Description

Geovax Labs Inc is us-based clinical-stage biotechnology company. It is engaged in developing immunotherapies and vaccines against cancers and infectious diseases using a novel patented Modified Vaccinia Ankara-Virus Like Particle (GV-MVA-VLP) vector vaccine platform. The development programs of the company focused on preventive vaccines against Human Immunodeficiency Virus (HIV), Zika Virus, hemorrhagic fever viruses, and malaria, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers. The product pipeline includes HIV Preventive Vaccine, Hemorrhagic Fever Vaccines, Zika Vaccine, Malaria vaccine, and Cancer Immunotherapy.

Contact
1900 Lake Park Drive, Suite 380
Smyrna, GA, 30080
T +1 678 384-7220
Industry Biotechnology
Most Recent Earnings Sep 30, 2022
Fiscal Year End Dec 31, 2022
Employees 11